Literature DB >> 27882397

Reply by L. Maffioli.

Lorenzo Maffioli1, Luca Dellavedova2, Luigia Florimonte3.   

Abstract

Year:  2017        PMID： 27882397     DOI： 10.1007/s00259-016-3570-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  9 in total

1.  Can survival be prolonged for patients with hormone-resistant prostate cancer?

Authors:  A R Zlotta; C C Schulman
Journal:  Lancet       Date:  2001-02-03       Impact factor: 79.321

2.  Strontium-89 for prostate cancer with bone metastases: the potential of cancer control and improvement of overall survival.

Authors:  Isao Kuroda
Journal:  Ann Nucl Med       Date:  2013-10-15       Impact factor: 2.668

3.  A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate.

Authors:  J H Turner; P G Claringbold
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

4.  Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial.

Authors:  S M Tu; R E Millikan; B Mengistu; E S Delpassand; R J Amato; L C Pagliaro; D Daliani; C N Papandreou; T L Smith; J Kim; D A Podoloff; C J Logothetis
Journal:  Lancet       Date:  2001-02-03       Impact factor: 79.321

5.  Palliation and survival after repeated (188)Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis.

Authors:  Hans-Jürgen Biersack; Holger Palmedo; Andrej Andris; Stefan Rogenhofer; Furn F Knapp; Stefan Guhlke; Samer Ezziddin; Jan Bucerius; Dirk von Mallek
Journal:  J Nucl Med       Date:  2011-10-05       Impact factor: 10.057

6.  Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial.

Authors:  C Collins; J F Eary; G Donaldson; C Vernon; N E Bush; S Petersdorf; R B Livingston; E E Gordon; C R Chapman; F R Appelbaum
Journal:  J Nucl Med       Date:  1993-11       Impact factor: 10.057

7.  Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.

Authors:  A T Porter; A J McEwan; J E Powe; R Reid; D G McGowan; H Lukka; J R Sathyanarayana; V N Yakemchuk; G M Thomas; L E Erlich
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-04-02       Impact factor: 7.038

Review 8.  153Sm-EDTMP for bone pain palliation in skeletal metastases.

Authors:  Carlo L Maini; Serenella Bergomi; Luisa Romano; Rosa Sciuto
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-04       Impact factor: 9.236

9.  Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer.

Authors:  Sergio Ricci; Giuseppe Boni; Ilaria Pastina; Dario Genovesi; Claudia Cianci; Serena Chiacchio; Cinzia Orlandini; Mariano Grosso; Abedallatif Alsharif; Aldo Chioni; Samantha Di Donato; Francesco Francesca; Cesare Selli; Domenico Rubello; Giuliano Mariani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-23       Impact factor: 10.057
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.